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Abstract 
Chronic lymphocytic leukaemia (CLL)  is the most common adult leukaemia and, in some patients, 
is accompanied by resistance to both chemotherapeutics and immunotherapeutics. In this review we 
will discuss the role of tumour associated macrophages (TAMs) in promoting CLL cell survival and 
resistance to immunotherapeutics. In addition, we will discuss mechanisms by which TAMs 
suppress T-cell mediated antitumour responses.  Thus, targeting macrophages could be used to i) 
reduce the leukaemic burden via the induction of T-cell-mediated antitumour responses, ii) to 
reduce pro-survival signalling and enhance response to conventional chemotherapeutics or iii) 
enhance the response to therapeutic antibodies in current clinical use. 
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Chronic Lymphocytic Leukaemia (CLL). 
Chronic lymphocytic leukaemia is a B cell lineage-derived blood cancer characterised by an 
accumulation of leukaemic cells within the blood, bone marrow and lymphoid tissues [1]. Whilst 
the clinical course of CLL is varied, it usually presents as indolent disease which endures for a 
variable length of time.  Conversion of CLL from the quiescent (stable disease) phase to disease 
requiring treatment (progressing disease) occurs in approximately 70% of patients and is often 
associated with reduced lymphocyte doubling time, del(17p), TP53 and IKZF3 mutations [2, 3]. 
Whilst we often refer to CLL as being stable or progressive it may be more realistic to view CLL as 
a disease that exists on a spectrum spanning “stable” through to disease requiring treatment. We 
know that CLL development, progression and relapse are accompanied by multiple mutational 
events [2, 3], but it is also clear that the microenvironment contributes to disease progression and 
responses to chemo-immunotherapeutic regimes. Of central importance to CLL are interactions 
between the leukaemic cells and the microenvironment within the bone marrow, lymphoid tissues 
and the circulation.  The CLL microenvironment is shaped by a complex network of cytokines and 
chemokines, as well as direct interactions of malignant B cells with CD4+ and CD8+ T-cells, NK 
T-cells, and specialised macrophages often referred to as nurse like cells (NLCs) or tumour 
associated macrophages (TAMs). A better understanding of the role of the microenvironment and 
its relationship with leukaemic CLL cells has identified several events with considerable potential 
for translation into patient treatments. In particular, tumour associated macrophages (TAM) are 
important contributors to CLL development and progression as well as effectors of antibody-based 
immunotherapy.  In this review we focus on the duality of the roles of TAMs, in particular their 
pro-tumourogenic and immune-suppressive role in CLL as well as their role as immune effectors of 
therapeutic antibodies.  
 
 
Macrophage lineage. 
Macrophages are an essential component of the innate immune system and are comprised of 
resident tissue macrophages as well as monocyte-derived macrophages. Many tissue macrophages 
are derived from the early embryonic yolk sac or liver [4]. Post-partum, tissue macrophages are 
either derived via self-renewal of resident tissue macrophages or through the attraction and 
subsequent differentiation of monocytes. In the latter instance, haemopoietic stem cells differentiate 
into two progenitor cell lineages namely myeloid progenitor cells (myelopoiesis) and lymphoid 
progenitor cells (lymphopoiesis) [5]. Lymphopoiesis gives rise to B-cells, T-cells and NK-cells 
whereas myelopoiesis gives rise to erythrocytes, monocytes, granulocytes and platelets [5-7]. 
Progenitor cells of both lineages give rise to differentiated cells that are released into the 
bloodstream where they remain or can be induced to undergo further differentiation within specific 
tissue sites [8-10]. In the post-partum setting, monocytes are derived from macrophage and 
dendritic cell (DC) progenitor cells (MDPs), which can differentiate into dendritic cells or 
macrophages in peripheral tissue sites, (Figure 1) [11-13]. Activated dendritic cells migrate to 
secondary lymphoid organs and present antigen to lymphocytes such as T-cells [14, 15], a key event 
in the initiation of adaptive immune responses. In contrast, macrophages have tissue-specific 
functions [11, 12, 16-18] and largely remain within the peripheral tissue after activation [9]. 
Macrophages present antigens and are effectors of Fc gamma receptor (FcγR)-dependent cell 
elimination via antibody-dependent cell mediated cytotoxicity (ADCC) and antibody-dependent 
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phagocytosis (ADP). More recently, it has emerged that TAMs can suppress T-cell mediated 
antitumour responses via PI3Kγ mediated immune response [19, 20]. In addition, macrophages 
regulate tissue homeostasis through the modulation of metabolism, tissue damage sensing, and 
tissue remodelling [11, 16].  
 
Whilst macrophages are traditionally thought as phagocytes with activity against infectious 
particles and cancer cells, it has become evident that multiple macrophage phenotypes exist that 
display a wide repertoire of functional capabilities [21]. Macrophages are classified by the 
expression of cell surface markers and their functional activation status. Classically, macrophages 
activated by IFNγ or microbial components were referred to as M1 macrophages [22], which 
release pro-inflammatory cytokines (TNF-a, IL-12) and activate T-cells. On the other hand, M2 
macrophage-phenotypes were induced by IL-4/IL-13 and characterised by anti-inflammatory 
effector molecules (IL-10, TGF-beta, HO-1, and arginase) that modulate inflammatory responses, 
and control wound healing and tissue regeneration [22]. More recently, it has become accepted that 
macrophages display considerable phenotypic plasticity where the experimentally induced “M1”-
like and “M2”-like phenotypes are the extreme ends of the spectrum [21]. Macrophages 
phenotypically adapt to suit the microenvironment in response to various stimuli and cytokines. For 
example, within an infectious microenvironment macrophages may acquire an “M1” state whereas 
within cancerous tissue there are different cues that induce “M2”-like properties [23-25].  Multiple 
Figure 1. Haematopoietic lineage of macrophages. The haematopoietic cells in bone marrow 
differentiate into myeloid (myelopoiesis) or lymphoid progenitor cells (lymphopoiesis). 
Lymphopoiesis gives rise to B-cells, T-cells and NK-cells whereas myelopoiesis involves two 
progenitors namely granulocyte–monocyte progenitors (GMPs) and megakaryocyte-erythrocyte 
progenitors (MEPs). Macrophage and dendritic cell progenitor cells (MDPs) give rise to 
monocytes which in turn differentiate into dendritic cells (DCs) and macrophages after recruitment 
to peripheral tissue sites.  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT 5 
 
 
studies have shown that the diversity and nature of the macrophage infiltrate in tumours may have 
either negative or positive prognostic implications depending on the tumour type [26-28]. This 
suggests that the infiltration of macrophages into a tumour is not only dependent on the tumour type 
but is dependent on, and may in turn modify, the behaviour of the tumour.  These observations 
suggest that macrophages can potentially both promote the survival of tumour cells (pro-
tumourogenesis) whilst also being mediators of tumour cell killing. Indeed, recent studies have 
shown that the pro-tumourogenic and immunosuppressive properties of tumour associated 
macrophages can be modulated by the PI3K/mTOR pathway which is actionable using clinically 
available agents [29, 30]. Thus, tracking macrophage phenotypes in the context of malignancy will 
be informative since it can provide an assessment of whether the malignant cells exist within the 
context of a pro- or anti-tumourogenic environment which may guide targeted therapies [31, 32]. It 
is this paradox that makes macrophages such a compelling target for anticancer therapies [31, 33]. 
 
  
The role of macrophages in CLL pathogenesis  
Macrophages both support the functioning of normal tissue-specific parenchymal cells and 
malignant cells, and are dependent on the signals generated by the parenchymal cells in the local 
environment [11, 22, 34, 35] for their differentiation. In CLL, evidence supports a “symbiotic” 
relationship between the malignant CLL cells and tumour associated macrophages, (Figure 2). For 
example, TAMs are required to maintain the survival of the malignant B cells within the bone 
marrow [36-39]. 
 
During conversion from the normal to neoplastic state, B cells start to secrete factors that attract 
circulating monocytes into the developing tumour niche [40] and induce them to differentiate into 
macrophages, which are characterised by high expression of surface markers such as CD14+, 
CD68, CD163 and CD206 [37, 41], consistent with an “M2”-like phenotype and functionality [27]. 
These macrophages have been shown to be functionally and transcriptomically indistinguishable 
from NLCs [42-45]. The term NLC specifically refers to in vitro cultures of monocyte-derived M2-
like macrophages isolated from PBMCs and are the functional equivalent of TAMs located in vivo 
within CLL tissues (ie NLCs = CLL-specific TAMs)[36]. NLCs are generated following the in vitro 
co-culture of CD14+ monocytes from either healthy donors or CLL patients with CD19+ CLL cells.  
In these cultures, the CLL cells induce NLC differentiation, which is accompanied by the 
production of cytokines by NLCs that promote the survival of the CLL cells [41] (Figure 2).  
Significantly, B cells from healthy donors are incapable of inducing a NLC phenotype in 
monocytes, and these monocytes do not support the survival of CLL cells [41].  Thus, malignant 
CLL cells induce the differentiation of NLCs which, in turn, secrete factors that promote the 
survival of the CLL cells.  This indicates that targeted depletion of NLCs (or their in vivo 
equivalent, CLL-specific TAMs) may be a potential therapeutic strategy to reduce the leukaemic 
burden in CLL patients.  
 
Due to the critical nature of the CLL:NLC interaction, identifying the secreted factors and 
membrane receptors that co-ordinate these events has been the subject of much study. Notably, this 
interaction appears to be independent of direct cell-to-cell contact [37, 41, 46, 47]. For example, in 
vitro studies using transwell-culturing systems, in which the NLCs and CLL cells are separated by a 
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membrane, showed that direct contact of NLCs to CLL cells was not required for the pro-survival 
signals from the NLCs [46]. The tissue niche of CLL comprises a complex cocktail of cytokines 
and chemokines that induce a prosurvival signal to CLL cells [46, 48-50]. These cytokines and 
chemokines play a crucial role in driving the ‘symbiotic’ relationship and are derived from the CLL 
cells, monocytes, TAMs/NLCs, as well as accessory stromal cells. For example, interleukin-4 (IL-
4) [51, 52], IL-13 [53] and IL-10 [54] are secreted by CLL cells and promote M2-like properties in 
monocytes and NLCs. Significantly, the M2-like phenotype has been linked to localised 
immunosuppression mediated via reduced T-cell infiltration and T-cell mediated anti-tumour 
responses [20, 29]. The M2-like NLCs activate pro-survival responses in CLL cells via secreted 
factors such as insulin-like growth factor-1 (IGF-1) [55, 56], IL-8 [57], CCL2 [49] and CXCL12 
[58] thereby stimulating an increased leukaemic burden. The leukaemic burden within the tissue 
niche is further increased by the continued recruitment of circulating monocytes to the CLL niche 
resulting in differentiation to M2-like NLCs induced in a microenvironment rich in chemokines 
such as CCL3, CCL4 [59], CCL2, CXCL12, CXCL13, CXCL19 and CXCL20 [60].  In particular, 
high levels of CCL3 and CCL4 in the CLL environment have been shown to attract monocytes via 
signalling through CCR1 and CCR5 [61]. Recruitment to the tumour niche is further enhanced by 
the binding of CCL2 to CCR2 and CCR4 on tissue-resident macrophages and the subsequent 
activation of migration [61]. Thus, the tumour niche is a self-sustaining immune suppressive 
environment in which leukaemic cells encourage an increase in the numbers of M2-like 
NLCs/TAMs, which provide pro-survival factors for the CLL cells as well as suppress anti-tumour 
immunity within the CLL microenvironment. 
 
 
Figure 2. Symbiotic relationship between CLLs and TAMs/NLCs. Chronic lymphocytic 
leukaemia (CLL) originates from transformed B cells that exist in a symbiotic relationship with 
accessory NLC cells. CLL & NLCs create a microenvironment that attracts and skews 
macrophages to acquire an M2-phenotype. Chemo-attractants secreted by CLLs recruit tissue-
resident macrophages and newly matured monocyte-derived macrophages to the CLL niche 
where they acquire the M2-like phenotype (NLCs). The NLCs then secrete cytokines and 
chemokines which in turn provide prosurvival signals for CLLs and hence the cycle continues.   
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TAMs/NLCs as a therapeutic target  
Two major activities attributed to NLCs/TAMs are, 1) the capability to induce pro-tumour 
survival signals and 2) an ability to dampen/suppress T-cell mediated anti-tumour immunity [19, 
20, 62-64]. TAMs associated with the bone marrow trephines from CLL patients display M2-like 
macrophage markers [46-48, 65]. The pro-survival signals for the CLL cells detailed in the 
preceding section also induce resistance of CLL cells to chemotherapeutics and suppress T-cell 
mediated anti-tumour immunity [20, 29, 37]. The critical dependence of CLL cell survival upon 
TAMs/NLCs was elegantly illustrated by Galletti et al. [66], who demonstrated that liposomal 
bisphosphonate (Clodrolip) or CSF1R signalling blockade in CLL mouse models depleted tissue 
macrophages resulting in the loss of TAMs and subsequent death of malignant B cells via the TNF 
pathway. This had the net effect of reprogramming the tumour microenvironment to an anti-
tumorigenic state [63, 67]. It is worth noting that non-liposomal formulations of bisphosphonates 
are in widespread use for osteoporosis and treatment of lytic bone metastases without adverse 
immune effects.  Finally, an independent study recently confirmed these findings and suggested that 
disruption of the macrophage-malignant cell axis by inhibition of macrophage Lyn/BTK could 
inhibit the pro-survival (nurse-like) properties of macrophages resulting in reduced CLL burden 
[39]. Thus, direct targeting of the NLC/TAMs within the CLL microenvironment remains a 
potentially valuable, yet untested, treatment for reducing CLL tumour burden in patients. 
 
Another implication of targeting TAMs/NLCs is the potential to remove a major 
immunosuppressive stimulus from the tumour microenvironment. In particular, it has been noted 
that TAMs possess a PI3Kγ-dependent immune suppressor phenotype which is independent of an 
additional role in permitting immune checkpoint activity within the tumour microenvironment [19, 
68]. Recognition of these new roles of M2-like TAMs supports studies focusing on “driving” the 
macrophage phenotype towards a more “M1” phenotype [69, 70] rather than ablating all 
macrophages [20, 30, 68]. For example, recent studies in models of pancreatic cancer and 
melanoma have shown that targeted inhibition of PI3Kγ by pharmacological inhibitors or genetic 
depletion of macrophage PI3Kγ promoted the conversion of M2-like TAMs to an M1-like 
phenotype [29, 52, 63]. The net effect of this was to increase activated T-cell infiltrates within the 
tumour resulting in reduced tumour load due to a T-cell mediated anti-tumour response [20, 29]. 
Complementing this, recent studies determined that the enhanced anti-tumour responses that 
occurred following inhibition of macrophage PI3Kγ were associated with increased expression of 
immune checkpoint molecules [52, 63].  Finally, it was shown that a combination of a PI3Kγ 
inhibitor plus an immune checkpoint inhibitor was able to induce significantly enhanced tumour 
clearance in multiple tumour models [52, 63]. These data suggest that targeted inhibition of the 
tumour suppressive properties of TAMs combined with inhibition of immune checkpoint 
regulation, within the tumour microenvironment is likely to induce significant and durable 
responses in patients. Potential off-target effects of such therapies may include autoimmune disease 
and altered responses to infection, which could potentially limit their application. However, early 
studies with immune checkpoint inhibitors alone or PI3K inhibitors alone suggests these effects 
may be manageable. Thus, it is reasonable to hypothesise that targeted reprogramming of 
macrophages in the CLL niche could have the potential to transform management of CLL.  
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Bruton’s tyrosine kinase (BTK) inhibitors such as ibrutinib, have shown great promise in CLL with 
durable responses in both relapsed/refractory [71] disease and as an initial treatment [72]. Whilst 
these effects are generally attributed to the action of BTK inhibition on BCR function and B cell 
survival there is emerging evidence that part of their success is attributable to effects on 
macrophages and other immune effector cells [73, 74]. For example, evaluation of blood samples 
and bone marrow trephines from a phase II study of 80 patients receiving ibrutinib showed marked 
reductions in multiple cytokines such as CCL3, CCL4 & CXCL13 [73]. These cytokines are 
required for recruitment of macrophages to the CLL niche [73].  Thus, reduced recruitment will 
result in reduced pro-survival sigaling and hence reduced leukemic burden.  In addition, 
examination of bone marrow trephines from ibrutinib treated patients revealed reduced interaction 
between CLL cells and TAMs [73].  Finally, Boissard noted that NLCs protected CLL cells from 
the apoptotic effects of therapeutic concentrations of ibrutinib in vitro [74]. Combined, these data 
suggest that the direct anticancer activity of ibrutinib on CLL cells may be aided by i) a reduced 
ability to recruit TAMs to the CLL niche and ii) an inhibition of direct CLL:TAM interaction.  This 
would result enhanced the therapeutic response to ibrutinib due to the reduced prosurvival signal 
present within the CLL niche.  
 
Macrophages as an immune effector of therapeutic antibodies.  
In the previous sections we discussed the pro-survival and immunosuppressive roles of 
NLCs/TAMs in CLL. These highlighted the therapeutic potential of targeting NLCs/TAMs as a 
means of reducing the leukaemic burden or activating T-cell mediated antitumour responses.  
However, NLCs/TAMs are also potent mediators of antibody-dependent immune responses. 
Antibodies induce cytotoxic effector functions of innate immune cells such as antigen-dependent 
phagocytosis (ADP) and antigen-dependent cell mediated cytotoxicity (ADCC) mediated by both 
macrophages and NK-cells [75, 76]. Monoclonal antibodies are an important component of therapy 
for CLL and thus preserving or enhancing existing macrophage function may, paradoxically, be of 
benefit to CLL patients.  
 
IgG antibodies display diversity in their antigen-binding Fab domains.  There is also diversity in 
the IgG Fc domain, which facilitates binding to immune effector cells [77]. Monoclonal antibodies 
for clinical use in CLL have been developed against CD20, CD47, CD52 and CD62L epitopes [42, 
76, 78, 79]. Diversity in the structure of these IgG antibodies, particularly the Fc region, results in a 
spectrum of immune responses directed against antibodies bound to the malignant cell.  Responses 
include complement-dependent cytotoxicity, phagocytosis, as well as cell-mediated cytotoxicity by 
NK cells, neutrophils, monocytes, macrophages, dendritic cells, and eosinophils [76, 79, 80]. 
Further work remains to be undertaken to fully characterise the spectrum of effector functions 
elicited by each monoclonal antibody. However, it is clear from murine models [76, 81] and human 
studies [80] that monocytes and macrophages are dominant effector cells in some settings. For 
example, the induction of an immune response to different engineered antibodies was shown to be 
dependent upon the binding affinity for the Fc receptors expressed by macrophages [82]. Time-
lapse fluorescence video microscopy imaged CLL cells treated with an anti-CD62L antibody and 
revealed rapid binding of the target CLL cells to the NLCs derived from CLL patients. These bound 
CLL cells were rapidly internalised and killed by the NLCs [83].  Given the efficiency with which 
the macrophages can mount a cytotoxic response to therapeutic antibodies it is surprising that 
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tumour clearance is not profound and durable.  However, it is clear that, as with most therapeutic 
antibodies in use today, that acquired or inherent resistance can develop which significantly reduces 
their current clinical efficacy. 
 
Macrophage-mediated therapeutic antibody resistance in CLL. 
Similar to other cancers, inherent and/or acquired resistance to therapeutic antibodies is common 
in CLL, and in the relapsed setting, is a significant challenge in treating CLL patients [84, 85]. 
Recently, we and others have made significant progress in understanding the molecular mechanisms 
that drive resistance to therapeutic antibodies in CLL. Therapeutic monoclonal IgG antibodies bind 
to their cognate target on CLL cells to form an immune complex that is recognised by, and binds to, 
type I Fc receptors (FcγR) on macrophages. This interaction with a tumour-specific immune 
complex is the basis for the anti-tumour activity of macrophages. Thus, it is important to understand 
FcγR biology in the context of a major immune effector cell type, the macrophage, in order to 
understand resistance mechanisms. To date, six different classes of FcγRs (FcγRI, FcγRIIA, 
FcγRIIB, FcγRIIC, FcγRIIIA and FcγRIIIB) have been described.  Activating FcγRs comprise 
FcγRI, IIa, IIc, IIIa and IIIb, and induce ADCC/ADP via a cascade of signalling events involving 
Lyn, Syk, PI3K and Btk activation/phosphorylation [67, 75, 86, 87]. In contrast, FcγRIIb inhibits 
ADCC/ADP tumour cell killing via activation of phosphatases such as Ship1/2, which catalyse the 
conversion of PIP3 to PIP2 thus blocking FcγR-dependent activation [88, 89] (Figure 3). Hence, 
FcγR-dependent events (e.g. ADCC or ADP) are controlled by the balance between activating 
(referred to collectively as ITAM) and inhibitory (referred to as ITIM) signalling pathways within 
the effector cells. Most importantly, ADCC and ADP responses to therapeutic antibodies are 
determined by the ratio of ITAM/ITIM signalling pathways [42, 77, 90]. For example, a low 
ITAM/ITIM ratio would reflect a poor response and a high ITAM/ITIM ratio would favour a good 
 
Figure 3. FcγR signalling pathway in NLCs/TAMs. Diagram illustrates the FcγR activating 
pathway (ITAM) and the opposing inhibitory (ITIM) pathway present in NLCs derived from CLL 
patients.  Signalling through ITAM is favoured in patients with stable disease whereas patients 
with progressive disease display reduced ITAM signalling resulting in increasing dominance of 
FcγRIIb-dependent ITIM signalling. 
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therapeutic response to antibodies [42].  
Interventions that increase the ITAM/ITIM ratio would be predicted to induce considerable 
therapeutic benefits. This concept was exploited with the development of the glyco-engineered anti-
CD20 antibody, obinutuzumab, which was designed to display a bias for binding activating FcγRs 
and in this way favour an ADCC response [77, 91]. More recently, we have shown that NLCs 
derived from patients with progressive disease are less effective at facilitating monoclonal antibody 
mediated CLL cell cytotoxicity compared to NLCs derived from patients with stable disease.  This 
was attributable to a loss of signalling through the ITAM pathway resulting in increased dominance 
of signalling through the ITIM pathway and a reduced capacity to participate in ADCC and ADP in 
response to a therapeutic antibody.  Significantly, this was an actionable event since treatment of 
antibody-resistant CLL patients’ PBMCs with a SHIP1 inhibitor resulted in the reinstatement of 
ADCC and ADP responses to therapeutic antibodies [42] (Figure 3).  These data suggest that 
targeting FcγRIIb function with small molecular weight compounds (eg SHIP1/2 inhibitors) or a 
therapeutic antibody targeting the FcγRIIb receptor [92] may be of clinical value in enhancing 
therapeutic antibody responses.  
 
 
Conclusion 
NLCs are a specialised form of TAM found in the microenvironment that play a dual role in 
CLL. In the first instance, NLCs provide survival signals and impair T-cell mediated tumour 
immunity, thereby contributing to the survival of the malignant B cells in their tissue niche. 
Targeted ablation of NLCs has been shown to reduce tumour burden in experimental models of 
CLL thus highlighting their potential importance as a therapeutic target. In addition, targeting the 
TAM-dependent immune suppression using PI3Kγ inhibitors in models of CLL has also shown in 
vivo activity.  However, NLCs have also been shown to be critical effectors of the response to 
existing chemo-immunotherapeutic combinations used in the treatment of CLL. Significantly, 
resistance to therapeutic antibodies is an acquired phenotype of NLCs and can be reversed with 
SHIP1 inhibitors.  Thus, targeting TAMs/NLC function is a novel therapeutic strategy that could 
directly a) remove pro-survival cues from the CLL microenvironment, b) stimulate macrophage-
dependent and T-cell mediated antitumour responses and c) optimize responses to existing 
therapeutic antibodies. 
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